Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 3—March 2018
Dispatch

Drug Resistance of Mycobacterium tuberculosis Complex in a Rural Setting, Angola

Ariadna Rando-Segura1, María Luisa Aznar1, María Milagros Moreno, Mateu Espasa, Elena Sulleiro, Cristina Bocanegra, Eva Gil, Arlete N.E. Eugénio, Carlos Escartin, Adriano Zacarias, Josep Vegue, Domingos Katimba, María Carmen Vivas, Estevao Gabriel, María Concepción Marina, Jacobo Mendioroz, María Teresa López, Tomas Pumarola, Israel Molina, and María Teresa TórtolaComments to Author 
Author affiliations: Vall d’Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (A. Rando-Segura, M.L. Aznar, M. Espasa, E. Sulleiro, C. Bocanegra, E. Gil, C. Escartin, J. Vegue, M.C. Vivas, M.C. Marina, J. Mendioroz, T. Pumarola, I. Molina, M.T. Tórtola); Hospital Nossa Senhora da Paz, Cubal, Angola (M.L. Aznar, M.M. Moreno, C. Bocanegra, E. Gil, A.N.E. Eugénio, A. Zacarias, D. Katimba, E. Gabriel, M.T. López)

Main Article

Table 1

Resistance to first-line antituberculosis drugs among Mycobacterium tuberculosis complex isolates, Cubal, Angola, April 2014–July 2015*

Phenotypic drug susceptibility
 Isolates from new cases, n = 225
 Isolates from retreatment cases, n = 83
No.
 % (95 CI)
 No.
 % (95 CI)
Susceptible to all 5 first-line drugs 167 74.2 (68.1–79.5) 14 16.9 (10.3–26.3)
Resistance to any drug
 58
 25.8 (20.5–31.9)
69
 83.1 (73.7–89.7)
Any resistance to the following
INH 47 20.9 (16.1–26.7) 66 79.5 (69.6–86.8)
RIF 20 8.9 (5.8–13.3) 61 73.5 (63.1–81.8)
STM 25 11.1 (7.6–15.9) 42 50.6 (40.1–61.1)
EMB 10 4.4 (2.4–8.0) 32 38.6 (28.8–49.3)
PZA
13
 5.8 (3.4–9.6)
37
 44.6 (34.4–55.3)
Overall monodrug resistance 31 13.8 (9.9–18.9) 7 8.4 (4.1–16.4)
INH only 21 9.3 (6.2–13.8) 4 4.8 (1.9–11.7)
RIF only 1 0.4 (0.1–2.5) 2 2.4 (0.7–8.4)
STM only 8 3.6 (1.8–6.9) 1 1.2 (0.2–6.5)
PZA only
 1
 0.4 (0.1–2.5)
0
 0.0 (0.0–4.4)†
Overall multidrug resistance 18 8.0 (5.1–12.3) 59 71.1 (60.6–79.7)
INH + RIF 4 1.8 (0.7–4.5) 12 14.5 (8.5–23.6)
INH + RIF + STM 2 0.9 (0.2–3.2) 5 6.0 (2.6–13.3)
INH + RIF + EMB 0 0.0 (0.0–1.7)† 3 3.6 (1.2–10.1)
INH + RIF + PZA 2 0.9 (0.2–3.2) 2 2.4 (0.7–8.4)
INH + RIF + STM + EMB 3 1.3 (0.5–3.8) 4 4.8 (1.9–11.7)
INH + RIF + STM + PZA 1 0.4 (0.1–2.5) 9 10.8 (5.8–19.3)
INH + RIF + EMB + PZA 1 0.4 (0.1–2.5) 4 4.8 (1.9–11.7)
INH + RIF + STM + EMB + PZA
 5
 2.2 (1.0–5.1)
20
 24.1 (16.2–34.3)
Overall polydrug resistance 9 4.0 (2.1–7.4) 3 3.6 (1.2–10.1)
INH + STM 5 2.2 (1.0–5.1) 0 0.0 (0.0–4.4)†
INH + EMB 1 0.4 (0.1–2.5) 0 0.0 (0.0–4.4)†
INH + PZA 2 0.9 (0.2–3.2) 0 0.0 (0.0–4.4)†
INH + STM + EMB 0 0.0 (0.0–1.7)† 1 1.2 (0.2–6.5)
INH + STM + PZA 0 0.0 (0.0–1.7)† 2 2.4 (0.7–8.4)
RIF + STM + PZA 1 0.4 (0.1–2.5) 0 0.0 (0.0–4.4)†

*EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin; STM, streptomycin.
†1-sided, 97.5% CI.

Main Article

1These authors were co-principal investigators for this article.

Page created: February 16, 2018
Page updated: February 16, 2018
Page reviewed: February 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external